High prevalence of low vitamin D and musculoskeletal complaints in women with breast cancer

Breast Journal

Volumn 16, Issue 6, 2010, Pages 609-616

  Napoli, Nicola ^a,b   Vattikuti, Swapna ^c   Ma, Cynthia ^a   Rastelli, Antonella ^a   Rayani, Anitha ^c   Donepudi, Ravi ^c   Asadfard, Mohammadreza ^a   Yarramaneni, Jayasree ^a   Ellis, Matthew ^b   Armamento Villareal, Reina ^a,d,e  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY CAMPUS BIO MEDICO   (Italy)

^c ST LUKE S HOSPITAL   (United States)

^d NEW MEXICO VA HEALTH CARE SYSTEM   (United States)

^e UNIVERSITY OF NEW MEXICO HEALTH SCIENCES CENTER   (United States)

Author keywords

aromatase inhibitors; breast cancer; osteoporosis; vitamin D

Indexed keywords

25 HYDROXYVITAMIN D; CALCIUM; VITAMIN D;

ADULT; AGED; ARTHRALGIA; ARTICLE; BONE DENSITY; BREAST CANCER; CLINICAL FEATURE; FEMALE; FEMUR; FRACTURE; HUMAN; LUMBAR SPINE; MAJOR CLINICAL STUDY; MUSCULOSKELETAL DISEASE; MYALGIA; OSTEOLYSIS; POSTMENOPAUSE; PREVALENCE; QUESTIONNAIRE; VITAMIN D DEFICIENCY;

ADULT; AGED; AGED, 80 AND OVER; BONE DENSITY; BREAST NEOPLASMS; FEMALE; HUMANS; MIDDLE AGED; MUSCULOSKELETAL DISEASES; PREVALENCE; VITAMIN D; VITAMIN D DEFICIENCY;

EID: 78449302457     PISSN: 1075122X     EISSN: 15244741     Source Type: Journal    
DOI: 10.1111/j.1524-4741.2010.01012.x     Document Type: Article

References (33)

1. Holick MF,. Vitamin D deficiency. N Engl J Med 2007; 357: 266-81.
2. Sato Y, Iwamoto J, Kanoko T, Satoh K,. Amelioration of osteoporosis and hypovitaminosis D by sunlight exposure in hospitalized, elderly women with Alzheimer's disease: a randomized controlled trial. J Bone Miner Res 2005; 20: 1327-33.
3. Holick MF,. High prevalence of vitamin D inadequacy and implications for health. Mayo Clin Proc 2006; 81: 353-73.
4. Perez EA,. Safety of aromatase inhibitors in the adjuvant setting. Breast Cancer Res Treat 2007; 105 (Suppl. 1): 75-89.
5. Perez EA,. Safety profiles of tamoxifen and the aromatase inhibitors in adjuvant therapy of hormone-responsive early breast cancer. Ann Oncol 2007; 18 (Suppl. 8): viii26-35.
6. Coombes RC, Hall E, Gibson LJ, et al. A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N Engl J Med 2004; 350: 1081-92. (Pubitemid 38298988)
7. Baum M, Budzar AU, Cuzick J, et al. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial. Lancet 2002; 359: 2131-9.
8. Howell A, Cuzick J, Baum M, et al. Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer. Lancet 2005; 365: 60-2.
9. Goss PE, Ingle JN, Martino S, et al. A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. N Engl J Med 2003; 349: 1793-802.
10. Buzdar A, Howell A, Cuzick J, et al. Comprehensive side-effect profile of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: long-term safety analysis of the ATAC trial. Lancet Oncol 2006; 7: 633-43.
11. Donnellan PP, Douglas SL, Cameron DA, Leonard RC,. Aromatase inhibitors and arthralgia. J Clin Oncol 2001; 19: 2767.
12. Bischoff-Ferrari HA, Giovannucci E, Willett WC, Dietrich T, Dawson-Hughes B,. Estimation of optimal serum concentrations of 25-hydroxyvitamin D for multiple health outcomes. Am J Clin Nutr 2006; 84: 18-28.
13. Chapuy MC, Preziosi P, Maamer M, et al. Prevalence of vitamin D insufficiency in an adult normal population. Osteoporos Int 1997; 7: 439-43.
14. Holick MF,. Vitamin D deficiency: what a pain it is. Mayo Clin Proc 2003; 78: 1457-9.
15. Plotnikoff GA, Quigley JM,. Prevalence of severe hypovitaminosis D in patients with persistent, nonspecific musculoskeletal pain. Mayo Clin Proc 2003; 78: 1463-70.
16. Neuhouser ML, Sorensen B, Hollis BW, et al. Vitamin D insufficiency in a multiethnic cohort of breast cancer survivors. Am J Clin Nutr 2008; 88: 133-9.
17. Geisler J, Lonning PE, Krag LE, et al. Changes in bone and lipid metabolism in postmenopausal women with early breast cancer after terminating 2-year treatment with exemestane: a randomised, placebo-controlled study. Eur J Cancer 2006; 42: 2968-75.
18. Morales L, Neven P, Timmerman D, et al. Acute effects of tamoxifen and third-generation aromatase inhibitors on menopausal symptoms of breast cancer patients. Anticancer Drugs 2004; 15: 753-60. (Pubitemid 39281298)
19. Rmamento-Villareal R, Villareal DT, Avioli LV, Civitelli R,. Estrogen status and heredity are major determinants of premenopausal bone mass. J Clin Invest 1992; 90: 2464-71.
20. Napoli N, Villareal DT, Mumm S, et al. Effect of CYP1A1 gene polymorphisms on estrogen metabolism and bone density. J Bone Miner Res 2005; 20: 232-9.
21. Hillner BE, Ingle JN, Chlebowski RT, et al. American Society of Clinical Oncology 2003 update on the role of bisphosphonates and bone health issues in women with breast cancer. J Clin Oncol 2003; 21: 4042-57.
22. Heaney RP, Davies KM, Chen TC, Holick MF, Barger-Lux MJ,. Human serum 25-hydroxycholecalciferol response to extended oral dosing with cholecalciferol. Am J Clin Nutr 2003; 77: 204-10.
23. Burstein HJ,. Aromatase inhibitor-associated arthralgia syndrome. Breast 2007; 16: 223-34.
24. Gloth FM III, Lindsay JM, Zelesnick LB, Greenough WB III,. Can vitamin D deficiency produce an unusual pain syndrome? Arch Intern Med 1991; 151: 1662-4.
25. Malabanan A, Veronikis IE, Holick MF,. Redefining vitamin D insufficiency. Lancet 1998; 351: 805-6.
26. Barnabei VM, Cochrane BB, Aragaki AK, et al. Menopausal symptoms and treatment-related effects of estrogen and progestin in the Women's Health Initiative. Obstet Gynecol 2005; 105 (5 Pt 1): 1063-73.
27. Egan KM, Signorello LB, Munro HM, Hargreaves MK, Hollis BW, Blot WJ,. Vitamin D insufficiency among African-Americans in the southeastern United States: implications for cancer disparities (United States). Cancer Causes Control 2008; 19: 527-35.
28. Perry HM III, Horowitz M, Morley JE, et al. Aging and bone metabolism in African American and Caucasian women. J Clin Endocrinol Metab 1996; 81: 1108-17.
29. Bell NH, Greene A, Epstein S, Oexmann MJ, Shaw S, Shary J,. Evidence for alteration of the vitamin D-endocrine system in blacks. J Clin Invest 1985; 76: 470-3. (Pubitemid 15227507)
30. Harris SS,. Vitamin D and African Americans. J Nutr 2006; 136: 1126-9.
31. Harris SS, Dawson-Hughes B,. Seasonal changes in plasma 25-hydroxyvitamin D concentrations of young American black and white women. Am J Clin Nutr 1998; 67: 1232-6.
32. McGill AT, Stewart JM, Lithander FE, Strik CM, Poppitt SD,. Relationships of low serum vitamin D3 with anthropometry and markers of the metabolic syndrome and diabetes in overweight and obesity. Nutr J 2008; 7: 4.
33. Vilarrasa N, Maravall J, Estepa A, et al. Low 25-hydroxyvitamin D concentrations in obese women: their clinical significance and relationship with anthropometric and body composition variables. J Endocrinol Invest 2007; 30: 653-8.